RESUMO
No disponible
Assuntos
Humanos , Feminino , Adulto , Doença de Crohn/tratamento farmacológico , Dermatite/tratamento farmacológico , Ustekinumab/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Doença de Crohn/complicações , Dermatite/etiologia , Resultado do Tratamento , Fatores de TempoRESUMO
We report on a child with a divided or kissing nevus of the penis with benign symmetric globular pattern on dermoscopic examination that evolved into a globular-reticular pattern after 1 year of follow-up. Divided nevus of the penis is exceedingly rare, with only four cases with dermoscopic findings reported to date. Dermoscopy seems to be useful when deciding on the most appropriate management of these cases.
Assuntos
Nevo/patologia , Neoplasias Penianas/patologia , Neoplasias Cutâneas/patologia , Criança , Dermoscopia , Humanos , Masculino , Pênis/patologiaRESUMO
Mid-dermal elastolysis (MDE) is an uncommon and probably underdiagnosed disorder of the elastic tissue. Clinical suspicion and histopathological confirmation are essential for the diagnosis. We report the case of a young woman who presented with this disorder after an inflammatory process during pregnancy and we review the main characteristics of this rare entity.
Assuntos
Tecido Elástico/patologia , Complicações na Gravidez/patologia , Dermatopatias/patologia , Adulto , Feminino , Humanos , GravidezRESUMO
No disponible
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Hepatite C Crônica/diagnóstico , Hepatite Autoimune/diagnóstico , Prurigo/etiologia , Biópsia , Ciclosporina/uso terapêuticoAssuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Doença de Darier/diagnóstico , Doença de Darier/tratamento farmacológico , Diclofenaco/uso terapêutico , Administração Cutânea , Adulto , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Géis , Humanos , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
No disponible
Assuntos
Humanos , Masculino , Idoso , Xantomatose/diagnóstico , Pavilhão Auricular/patologia , Otopatias/patologiaRESUMO
Omalizumab is a monoclonal anti-IgE antibody approved for the treatment of severe allergic asthma. There is increasing evidence in the literature of its usefulness in chronic urticaria. Herein, we report a retrospective case series of 15 patients with chronic idiopathic urticaria treated with omalizumab. We reviewed their medical records to assess the improvement achieved after 3 and 6 months of treatment. Complete response was defined as symptom disappearance that could be followed by discontinuation of antihistamines, and partial response as symptom improvement, but with symptom worsening when attempting to discontinue antihistamines. After 3 months of treatment, 12 patients responded, with partial response in 9 and complete response in 3. At 6 months, 8 of 10 patients continuing on omalizumab had a complete response and 2 a partial response. The results of the present retrospective series show the effectiveness of omalizumab in most treated patients, which is consistent with other recently published series and studies. These data support its role in the management of patients with chronic urticaria refractory to conventional treatments.
